Literature DB >> 19695938

[Intensity-modulated radiotherapy for cancers in childhood].

J Leseur1, C Carrie, E Le Prisé, V Bernier, V Beneyton, M A Mahé, S Supiot.   

Abstract

Approximately 40-50% of children with cancer will be irradiated during their treatment. Intensity-modulated radiotherapy (IMRT) by linear accelerator or helical tomotherapy improves dose distribution in target volumes and normal tissue sparing. This technology could be particularly useful for pediatric patients to achieve an optimal dose distribution in complex volumes close to critical structures. The use of IMRT can increase the volume of tissue receiving low-dose radiation, and consequently carcinogenicity in childhood population with a good overall survival and long period of life expectancy. This review will present the current and potential IMRT indications for cancers in childhood, and discuss the benefits and problems of this technology aiming to define recommendations in the use of IMRT and specific doses constraints in pediatry.

Entities:  

Mesh:

Year:  2009        PMID: 19695938     DOI: 10.1016/j.canrad.2009.07.006

Source DB:  PubMed          Journal:  Cancer Radiother        ISSN: 1278-3218            Impact factor:   1.018


  2 in total

Review 1.  The role of radiotherapy in adult medulloblastoma: long-term single-institution experience and a review of the literature.

Authors:  M Balducci; S Chiesa; D Chieffo; S Manfrida; N Dinapoli; A Fiorentino; F Miccichè; V Frascino; C Anile; V Valentini; B De Bari
Journal:  J Neurooncol       Date:  2011-07-31       Impact factor: 4.130

2.  Can We Spare the Pancreas and Other Abdominal Organs at Risk? A Comparison of Conformal Radiotherapy, Helical Tomotherapy and Proton Beam Therapy in Pediatric Irradiation.

Authors:  Emmanuel Jouglar; Antoine Wagner; Grégory Delpon; Loïc Campion; Philippe Meingan; Valérie Bernier; Charlotte Demoor-Goldschmidt; Marc-André Mahé; Thomas Lacornerie; Stéphane Supiot
Journal:  PLoS One       Date:  2016-10-20       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.